This is the text extract for 2012-01 Tender Notification Fax, browse documents here.

31 January 2012

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award a tender for Sole Subsidised Supply Status for a product included in the 2010/11 Invitation to Tender, dated 2 November 2010. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011 and in 2012. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A479270 - qA18036

Page 1 of 2

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Current subsidy (and price) New subsidy and price Sole supply brand (Supplier) Date of listing/subsidy change for tender winning brand Date of reference pricing of other listed brands Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting Loette (Pfizer) 1 July 2012 1 September 2012 1 December 2012 Microgynon 20 ED (Bayer)

Tab 20 mcg with Ethinyloestradiol levonorgestrel 100 mcg with Levonorgestrel and 7 inert tablets

$6.62 ($16.50)

$2.95

Ava 20 ED (Arrow)

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A4792700317 - qA18036

Page 2 of 2